JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
US4973577A
(en)
*
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
US5118667A
(en)
*
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
CA2086327A1
(en)
|
1991-05-10 |
1992-11-11 |
Lawrence S. Mathews |
Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
US6162896A
(en)
*
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
US5885794A
(en)
*
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
KR100255415B1
(ko)
|
1991-06-25 |
2000-05-01 |
브루스 엠. 에이센 |
비엠피-9 조성물
|
WO1993020207A1
(en)
*
|
1992-04-02 |
1993-10-14 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Use of restriction endonucleases against viruses, including hiv
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
EP0698095B1
(en)
|
1993-05-12 |
2004-04-28 |
Genetics Institute, LLC |
Bmp-10 compositions
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
US5831050A
(en)
*
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
CA2174098C
(en)
|
1993-10-14 |
2011-01-25 |
Douglas A. Melton |
Method of inducing and maintaining neuronal cells
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
US5863738A
(en)
*
|
1994-04-29 |
1999-01-26 |
Creative Biomolecules, Inc. |
Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
|
IL114397A0
(en)
*
|
1994-07-01 |
1995-10-31 |
Bioph Biotech Entw Pharm Gmbh |
Growth/differentiation factor of the TGF-beta-family
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
IL117175A
(en)
*
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
DE69636866D1
(en)
|
1995-04-11 |
2007-03-15 |
Gen Hospital Corp |
Reverse "two-hybrid"-systeme
|
EP0771873A3
(en)
*
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
CA2268001A1
(en)
|
1996-10-25 |
1998-05-07 |
G.D. Searle & Co. |
Circularly permuted erythropoietin receptor agonists
|
US6605699B1
(en)
*
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
CA2297489A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
CA2302525A1
(en)
|
1997-08-29 |
1999-03-04 |
Human Genome Sciences, Inc. |
Follistatin-3
|
DE69838454T2
(de)
|
1997-10-03 |
2008-02-07 |
Chugai Seiyaku K.K. |
Natürlicher menschlicher antikörper
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
EP1087998A1
(en)
|
1998-06-16 |
2001-04-04 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
JP2002524514A
(ja)
*
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
CA2343715C
(en)
|
1998-09-22 |
2004-05-18 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
US6472179B2
(en)
*
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
US20040009535A1
(en)
*
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
IL143266A0
(en)
*
|
1998-11-27 |
2002-04-21 |
Darwin Discovery Ltd |
Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
|
MXPA01007366A
(es)
|
1999-01-21 |
2002-06-04 |
Metamorphix Inc |
Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
AU777783B2
(en)
|
1999-04-19 |
2004-10-28 |
Kyowa Hakko Kogyo Co. Ltd. |
Proliferation inhibitor for androgen-independent tumor
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
SK8292002A3
(en)
|
1999-11-12 |
2002-12-03 |
Maxygen Holdings Ltd |
A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
|
EP1237565B1
(en)
|
1999-12-15 |
2006-03-08 |
Research Development Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
PT1311285E
(pt)
|
2000-05-15 |
2005-06-30 |
Hoffmann La Roche |
Composicao farmaceutica liquida contendo um derivado de eritropoietina
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
WO2002008277A2
(en)
|
2000-07-19 |
2002-01-31 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
EP2141243A3
(en)
|
2000-10-16 |
2010-01-27 |
Brystol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
AU2002225670B2
(en)
|
2000-11-20 |
2006-05-11 |
The Board Of Trustees Of The University Of Illinois |
Membrane scaffold proteins
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
WO2002043759A2
(en)
|
2000-12-01 |
2002-06-06 |
Wyeth |
Method and composition for modulating bone growth
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
TWI329129B
(en)
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
US7294472B2
(en)
*
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
US20040121008A1
(en)
|
2001-03-16 |
2004-06-24 |
Keiko Shiraishi |
Process for producing sustained release preparation
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
SI2116259T1
(sl)
|
2001-05-24 |
2012-11-30 |
Zymogenetics Inc |
Taci imunoglobulin fuzijski proteini
|
WO2002094864A2
(en)
|
2001-05-25 |
2002-11-28 |
Genset S.A. |
Human cdnas and proteins and uses thereof
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
KR100912852B1
(ko)
|
2001-07-17 |
2009-08-18 |
데이진 가부시키가이샤 |
PPAR δ활성화 작용을 측정하는 것을 특징으로 하는물질의 선택방법 및 약제
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
EP2298301B2
(en)
|
2001-12-06 |
2022-11-16 |
Fibrogen, Inc. |
Medicaments for treating anemia associated with kidney disease
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
BR0307907A2
(pt)
|
2002-02-21 |
2011-07-05 |
Wyeth Corp |
gasp1: proteìna contendo domìnio de folistatina
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
WO2003087162A2
(en)
*
|
2002-04-18 |
2003-10-23 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
KR20050083635A
(ko)
|
2002-08-16 |
2005-08-26 |
와이어쓰 |
Bmp-2 에스트로겐 반응 요소 및 이의 사용 방법
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
EP1592416B1
(en)
|
2003-02-07 |
2009-01-07 |
ProMetic BioSciences Inc. |
Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
|
US20040197828A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Gaddy Dana P. |
Method for diagnosis and treatment of bone turnover
|
WO2005028517A2
(en)
*
|
2003-05-09 |
2005-03-31 |
The General Hospital Corporation |
SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
|
JP5110877B2
(ja)
|
2003-06-02 |
2012-12-26 |
ワイス・エルエルシー |
神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用
|
WO2005014650A2
(en)
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
JP4987484B2
(ja)
*
|
2004-01-22 |
2012-07-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
補体結合が低下した抗癌抗体
|
US20050197292A1
(en)
*
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
US7625867B2
(en)
*
|
2004-03-26 |
2009-12-01 |
Acceleron Pharma Inc. |
BMP-3 propeptides and related methods
|
AU2005230854A1
(en)
*
|
2004-03-31 |
2005-10-20 |
Xencor, Inc |
BMP-7 variants with improved properties
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
CA2572330A1
(en)
|
2004-06-24 |
2006-01-05 |
Acceleron Pharma Inc. |
Gdf3 propeptides and related methods
|
JP2008507288A
(ja)
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ActRII受容体ポリペプチド、方法、および組成物
|
EP1794191B1
(en)
|
2004-08-05 |
2016-05-18 |
The Regents of The University of California |
Molecules with effects on cellular development and function
|
AU2005272646A1
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
MX2007005884A
(es)
|
2004-11-16 |
2008-02-12 |
Amgen Mountain View Inc |
Andamios de proteina y usos de los mismos.
|
NL1027887C2
(nl)
|
2004-12-24 |
2006-06-27 |
Bosch Gmbh Robert |
Transmissie met gebombeerde poelieschijven en een drijfriem.
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
EP2954903A1
(en)
|
2005-02-16 |
2015-12-16 |
The General Hospital Corporation |
Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
|
EP2295466A3
(en)
|
2005-04-25 |
2011-08-17 |
Pfizer Inc. |
Antibodies to myostatin
|
JPWO2006115274A1
(ja)
|
2005-04-26 |
2008-12-18 |
味の素株式会社 |
骨髄赤血球前駆細胞分化促進剤
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
KR20080056241A
(ko)
|
2005-09-28 |
2008-06-20 |
지모제넥틱스, 인코포레이티드 |
Il-17a 및 il-17f 길항제 및 그것의 사용 방법
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
KR20150115961A
(ko)
|
2005-11-23 |
2015-10-14 |
악셀레론 파마 인코포레이티드 |
액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
US20070149458A1
(en)
|
2005-12-06 |
2007-06-28 |
Amgen Inc. |
Uses of myostatin antagonists
|
EP1966183A4
(en)
|
2005-12-20 |
2010-12-29 |
Merck Frosst Canada Ltd |
HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
|
JP2009521452A
(ja)
|
2005-12-21 |
2009-06-04 |
シェーリング コーポレイション |
コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
|
EP1973909A2
(en)
|
2005-12-22 |
2008-10-01 |
Biogen Idec MA Inc. |
Transforming growth factor modulators
|
JP4925364B2
(ja)
|
2006-01-20 |
2012-04-25 |
ベックマン コールター, インコーポレイテッド |
鉄欠乏を検出する方法
|
JP2009531280A
(ja)
|
2006-01-25 |
2009-09-03 |
ウェルスタット セラピューティクス コーポレイション |
代謝障害を処置するための化合物
|
MX2008011022A
(es)
|
2006-02-28 |
2008-09-10 |
Wellstat Therapeutics Corp |
Compuestos para el tratamiento de trastornos metabolicos.
|
CA2650131A1
(en)
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
BRPI0713096A2
(pt)
|
2006-05-09 |
2012-10-16 |
Hemaquest Pharmaceuticals Inc |
métodos para tratar distúrbios sangüìneos
|
TW200803123A
(en)
*
|
2006-06-02 |
2008-01-01 |
Delta Electronics Inc |
Power converter and magnetic structure thereof
|
ATE547099T1
(de)
|
2006-07-21 |
2012-03-15 |
Lyne Lab Inc |
Flüssige zusammensetzungen aus calciumacetat
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
WO2008073292A2
(en)
|
2006-12-08 |
2008-06-19 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
|
JP5632582B2
(ja)
|
2006-12-14 |
2014-11-26 |
中外製薬株式会社 |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
EA202091230A3
(ru)
|
2006-12-18 |
2021-01-29 |
Акселерон Фарма Инк. |
Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
US9526759B2
(en)
|
2007-02-01 |
2016-12-27 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
PT2120999E
(pt)
|
2007-02-09 |
2012-12-10 |
Acceleron Pharma Inc |
Antagonista de activina-actriia e usos para promover o crescimento ósseo em doentes de cancro
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
MX2009012934A
(es)
|
2007-06-01 |
2009-12-15 |
Wyeth Corp |
Metodos y composiciones para modular la actividad de bmp-10.
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
US20090025308A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Deans Brian W |
Seismic support and reinforcement systems
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
PE20090510A1
(es)
|
2007-08-03 |
2009-05-22 |
Summit Corp Plc |
Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
US20100279409A1
(en)
|
2007-09-13 |
2010-11-04 |
Neil Robson |
Method for modifying celluar immune resonse by modulating activin activity
|
WO2009038745A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
BRPI0820387A2
(pt)
|
2007-11-21 |
2015-05-26 |
Amgen Inc |
Agentes de ligação de wise e epítopos
|
JP5638961B2
(ja)
|
2008-03-13 |
2014-12-10 |
ザ ジェネラル ホスピタル コーポレイション |
Bmpシグナル伝達経路のインヒビター
|
WO2009137075A1
(en)
*
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
AU2009244308A1
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
EP2315602A4
(en)
|
2008-06-26 |
2011-11-02 |
Acceleron Pharma Inc |
METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
|
CN107252486B
(zh)
|
2008-06-26 |
2021-10-22 |
阿塞勒隆制药公司 |
激活素-actrii的拮抗剂及在提高红细胞水平中的用途
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
DK2340031T3
(da)
|
2008-08-14 |
2019-07-15 |
Acceleron Pharma Inc |
Gdf-fanger til anvendelse ved behandling af anæmi
|
WO2010059861A1
(en)
|
2008-11-20 |
2010-05-27 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
CR20160443A
(es)
|
2008-11-26 |
2016-11-08 |
Amgen Inc |
Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional)
|
EP2387412A4
(en)
|
2009-01-13 |
2013-04-03 |
Acceleron Pharma Inc |
METHODS FOR INCREASING ADIPONECTIN
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
NZ595235A
(en)
|
2009-04-27 |
2013-06-28 |
Novartis Ag |
Compositions and methods for increasing muscle growth
|
MX355042B
(es)
|
2009-06-08 |
2018-04-02 |
Acceleon Pharma Inc |
Metodos para aumentar adipositos termogenicos.
|
EP3805259A1
(en)
|
2009-06-12 |
2021-04-14 |
Acceleron Pharma Inc. |
Truncated actriib-fc fusion proteins
|
CN105561295B
(zh)
|
2009-08-13 |
2020-03-20 |
阿塞勒隆制药公司 |
Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
|
KR102133683B1
(ko)
|
2009-09-09 |
2020-07-14 |
악셀레론 파마 인코포레이티드 |
ActRIIb 길항제들와 이의 투약 및 용도
|
EP2496247B1
(en)
|
2009-11-03 |
2017-08-23 |
Acceleron Pharma, Inc. |
Methods for treating fatty liver disease
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
WO2013006437A1
(en)
|
2011-07-01 |
2013-01-10 |
Novartis Ag |
Method for treating metabolic disorders
|
US20130243743A1
(en)
|
2011-10-17 |
2013-09-19 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ineffective erythropoiesis
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
US20140303068A1
(en)
|
2011-10-28 |
2014-10-09 |
Paranta Biosciences Limited |
Method of treating mucus hypersecretion
|
JP6145112B2
(ja)
|
2011-12-19 |
2017-06-07 |
アムジエン・インコーポレーテツド |
単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
EP2861620A2
(en)
|
2012-06-14 |
2015-04-22 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
|
CA2874117C
(en)
|
2012-07-02 |
2021-10-12 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
|
ES2753811T3
(es)
|
2012-10-24 |
2020-04-14 |
Celgene Corp |
Biomarcador para uso en el tratamiento de anemia
|
WO2014066487A2
(en)
|
2012-10-24 |
2014-05-01 |
Celgene Corporation |
Methods for treating anemia
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
ES2884095T3
(es)
|
2012-11-02 |
2021-12-10 |
Celgene Corp |
Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
|
US20150258120A1
(en)
|
2012-11-08 |
2015-09-17 |
Clearside Biomedical, Inc. |
Methods and devices for the treatment of ocular diseases in human subjects
|
US20150328249A1
(en)
|
2012-12-11 |
2015-11-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
WO2014152940A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素a之抗體及其用途
|
AU2014307589A1
(en)
|
2013-08-14 |
2016-02-11 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015089575A1
(en)
|
2013-12-16 |
2015-06-25 |
Paranta Biosciences Limited |
Method of diagnosis and treatment
|
EP3094751A4
(en)
|
2014-01-14 |
2017-06-07 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
US20170248609A1
(en)
|
2014-01-27 |
2017-08-31 |
Novartis Ag |
Biomarkers predictive of muscle atrophy, method and use
|
WO2015152183A1
(ja)
|
2014-03-31 |
2015-10-08 |
大日本住友製薬株式会社 |
進行性骨化性線維異形成症の予防剤及び治療剤
|
BR112016024319B1
(pt)
|
2014-04-18 |
2024-01-23 |
Acceleron Pharma Inc |
USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
CN106795224B
(zh)
|
2014-06-04 |
2021-05-18 |
阿塞勒隆制药公司 |
用促滤泡素抑制素多肽治疗病症的方法和组合物
|
BR112016029211A2
(pt)
|
2014-06-13 |
2018-01-30 |
Amgen Inc |
composição, método para inibir um crescimento tumoral sólido em um indivíduo, método para produzir uma proteína, método para inibir, reduzir ou tratar de caquexia em um indivíduo, método para tratar obesidade ou uma doença associada à obesidade e kit
|
AU2016261913B2
(en)
|
2015-05-13 |
2021-08-12 |
Acceleron Pharma Inc. |
Treatment of beta-thalassemia using ActRII ligand traps
|